Unicycive Therapeutics, Inc. (UNCY) earnings
UNCY earnings moved a median of +4.86% by the close. Quarterly and annual UNCY reports and results, each read against the price at its own news timestamp. Back to the UNCY overview →
10 measured UNCY earnings events.
Where these UNCY earnings landedvs 10 measured UNCY earnings reactions
| Middle 50% of UNCY earnings reactions | +2.77% to +7.08% |
|---|---|
| Median reaction (to close) | +4.86% |
| Measured reactions | 10 |
Point-in-time · zero look-ahead
Half of the 10 UNCY earnings events with a measured close landed between +2.77% and +7.08%; 80% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Unicycive Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.97% | +4.86% | |
| Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update | Press release | +0.97% | +4.86% | |
| Form 10-Q Unicycive Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +0.63% | +2.77% | |
| Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update | Press release | +0.63% | +2.77% | |
| Form 10-K Unicycive Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.65% | -0.81% | |
| Form 10-Q Unicycive Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +1.58% | +7.08% | |
| Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update | Press release | +1.58% | +7.08% | |
| Form 10-Q Unicycive Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +1.50% | +9.20% | |
| Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update | Press release | +1.50% | +9.20% | |
| Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update | Press release | +1.64% | -8.47% |
Keep exploring
More UNCY: analyst actions → · SEC filings → · UNCY overview →